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Detection of somatic mutations in non–small cell lung cancers (NSCLCs), especially adenocarcinomas, is
important for directing patient care when targeted therapy is available. Here, we present our experience with
genotyping NSCLC using the Ion Torrent Personal Genome Machine (PGM) and the AmpliSeq Cancer Hotspot
Panel v2. We tested 453 NSCLC samples from 407 individual patients using the 50 gene AmpliSeq Cancer Hotspot
Panel v2 from May 2013 to July 2015. Using 10 ng of DNA, up to 11 samples were simultaneously sequenced on
the Ion Torrent PGM (316 and 318 chips). We identified variants with the Ion Torrent Variant Caller Plugin, and
Golden Helix's SVS software was used for annotation and prediction of the significance of the variants. Three
hundred ninety-eight samples were successfully sequenced (12.1% failure rate). In all, 633 variants in 41 genes
were detected with a median of 2 (range of 0 to 7) variants per sample. Mutations detected in BRAF, EGFR,
ERBB2, KRAS, NRAS, and PIK3CA were considered potentially actionable and were identified in 237 samples, most
commonly in KRAS (37.9%), EGFR (11.1%), BRAF (4.8%), and PIK3CA (4.3%). In our patient population, all
mutations in EGFR, KRAS, and BRAF were mutually exclusive. The Ion Torrent Ampliseq technology can be utilized
on small biopsy and cytology specimens, requires very little input DNA, and can be applied in clinical laboratories
for genotyping of NSCLC. This targeted next-generation sequencing approach allows for detection of common and
also rare mutations that are clinically actionable in multiple patients simultaneously.
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Lung cancers are broadly classified as small cell or non–small cell
cancers (NSCLCs), with NSCLCs further subtyped largely on the
basis of histologic features and immunohistochemistry profile.
NSCLCs include adenocarcinoma (ADC), squamous cell carcinoma
(SqCC), large cell carcinoma, and other less common subtypes (e.g.,
adenosquamous carcinoma and sarcomatoid carcinoma) [1]. The
genomic profile of NSCLC is highly variable both across and within
histologic subtypes [2,3].
Incorporation of molecular analysis in the pathologic evaluation of
nonsquamous NSCLC is now considered the standard of care in
clinical practice [4–6]. Once the molecular profile of a tumor is
known, the appropriate use of targeted clinical therapies or eligibility
for clinical trials can be determined. It is desirable to have the ability
to analyze several genes simultaneously to assess for the presence of a
known clinically actionable variant in a tumor. In cases without
clinically actionably mutations, it is also beneficial to document the
genomic profile of a tumor should a targeted therapy be discovered. In
addition, immunotherapies may be an alternative therapeutic option
for patients who lack known actionable mutations, forming another
pathway to targeted therapy.
Next-generation sequencing (NGS) is one testing modality that
can detect multiple gene variants simultaneously, allowing for the
precise diagnosis of a tumor at the genetic level. The Ion Torrent
platform can be used in the clinical laboratory for sequencing of
NSCLC, among other cancer types, in an efficient and cost-effective
manner. In many instances, only a small biopsy or cytology specimen
is available for molecular testing; therefore, the ability to detect
known targetable driver mutations from a small amount of input
DNA is often required. Here, we present our experience with NGS
using the Ion Torrent Personal Genome Machine (PGM) to detect
somatic mutations in NSCLC; this assay covers 2855 COSMIC-cited
mutations in 50 cancer-related genes.
Methods
All NSCLCs with a diagnosis of ADC or poorly differentiated
NSCLC, favor ADC (small biopsy and cytology samples), and
adenosquamous carcinoma or those in which adenosquamous
carcinoma cannot be excluded are reflexively genotyped at our
institution. In May 2013, our laboratory introduced a targeted NGS
panel, the Ion AmpliSeq 50-gene Cancer Hotspot Panel v2, for this
purpose followed by reflex ALK fluorescence in situ hybridization
testing for tumors that are negative for EGFR, KRAS, and BRAF [4].
Rarely, an NSCLC of other histology (sarcomatoid, SqCC, or large
cell neuroendocrine carcinoma) was also tested on a per-request basis.
Institutional review board approval, including a waiver of consent,
was granted to review our genotyping experience in lung cancer.
DNA Extraction
Hematoxylin-eosin–stained slides of resection specimens, biopsy,
or fine needle aspiration (FNA) cell blocks were reviewed to
determine the area of tumor for extraction and the percent tumor
content within that area; a minimum of 10% tumor content was
considered acceptable for further processing. DNA was extracted
from 8 unstained sections (4 μm) using a manual extraction, the
Gentra Puregene Kit (Qiagen Inc., Valencia, CA), or the QIAamp
DNA FFPE Tissue Kit automated on the Qiacube Instrument (after
August 2015) (Qiagen Inc., Valencia, CA) according to the
manufacturer's instructions following deparaffinization with xylene.DNA quantification was performed using the Quant-iT PicoGreen
dsDNA Assay Kit (Thermo Fisher Scientific Inc.) according to the
manufacturer's directions on a TECAN microplate reader (Tecan
Group Ltd., Männedorf, Switzerland).
Sequencing
The validation of this targeted panel was previously reported [7].
Briefly, bar-coded libraries were prepared using 10 ng of DNA. Up to
11 samples were simultaneously sequenced on the Ion Torrent PGM
(Life Technologies, Rockville, MD) (316 and 318 chips) using the
manufacturer's recommended protocol. The Ion Torrent Variant
Caller Plugin v4.0 was used to align reads to the reference genome
hg19. All variant calls were initially filtered to remove benign
polymorphisms and noncoding and synonymous.
Variants. Golden Helix SNP and Variation Suite software
v.8.2.1 was used for annotation and prediction of the significance
of the variants. A report detailing the detected variants and resultant
amino acid changes was included in each patient's medical record.
Quality Assurance Metrics
At various steps in the sequencing process, all samples were subject
to six quality assurance measures (Table 1): minimum tumor
cellularity, DNA quantification, DNA quality, library quantification,
ISP quantification, and data analysis metrics [8].
Results
Four hundred fifty-three (453) samples from 407 individual patients
were submitted for sequencing from May 2013 to July 2015. There
were a total of 204 females and 203 males. All tumors were diagnosed
as NSCLC; the vast majority were ADC or poorly differentiated
carcinoma, favor ADC (n= 437). Additional histologic types included
cases where adenosquamous carcinoma could not be excluded (n= 8),
squamous cell carcinoma (n= 4), sarcomatoid carcinoma (n= 3), or
large cell neuroendocrine carcinoma (n= 1).
Quantity Not Sufficient (QNS) Cases
Overall, 55 of 453 samples tested (12.1%) from 48 individual
patients had an insufficient amount of material for sequencing; all of
these were of the ADC subtype. Of these, the lung core biopsies had
the highest failure rate comprising 42% (23/55) of all QNS
specimens (Figure 1A). Twenty-two of the patients whose sample
originally failed processing underwent sequencing with a different
sample in which 19 (86.4%) were successfully sequenced on the
second attempt. Twenty-six of the patients with QNS samples did
not undergo additional testing during the study period. In total, 378
of 407 patients (93%) had sequencing results.
Sequencing Results
Sequenced samples (n= 398) were from primary and metastatic
sites and consisted of the following: lung core biopsies (n= 110, 28%),
regional lymph node (LN) FNA (n= 92, 23%), excision of the
primary lung tumor (n= 59, 15%), biopsies of metastatic sites (other
than regional LN) (n= 51, 13%), lung FNAs (n= 38, 9%), cell block
of a fluid (pleural/pericardial) (n= 21, 5%), outside consult cases sent
for molecular testing (n= 18, 4%), and regional LN biopsies or
excisions (n= 9, 2%) (Figure 1B). Metastatic sites included the
following: abdominal metastasis (1), adrenal (4), bone (2,) brain (22,)
epidural tumor (1), paraspinal tumor (2), gastroesophageal junction
metastasis (1), inguinal LN (2), liver (4), neck LN (3), kidney (3),
pleural biopsy (3), skin metastasis (2), and spleen (1). Among the
Table 1. Quality Assurance Metrics Applied during the Preanalytic and Analytic Processing and Analysis of the Samples
QA Measure Method Acceptable Criteria
Minimum tumor cellularity Pathologist review N10%
DNA quantification PicoGreen 1.7 ng/μl of DNA *
DNA quality Kapa Library Quantification Kit (Kapa Biosystems, Wilmington, MA) Q129/Q41 N 0.4 *
Library quantification qPCR (7500 Fast Real-Time PCR System) (100 pM each) and Pooled (100 pM)
ISP quantification qPCR (Qubit 2.0 Fluorometer, Life Technologies) 10% TO 30%
(b10%: FAILED E-PCR N30%: POLYCLONAL AMPLIFICATION)
Data analysis metrics Ion Variant Caller Plug-in Golden Helix SVS Postsequencing metrics were established at the run, sample, and variant levels. †
* Samples must fail both DNA concentration and KAPA to be deemed quality not sufficient.
† For each run, the following sequencing metrics were verified: chip loading (N70.0%), usable sequences (N55.0%), polyclonality (b35.0%), and low-quality reads (b20.0%). For each individual sample, the metrics
assessed were on-target reads (N90.0%), coverage uniformity (N90.0%), and ≥95% amplicons with 500× coverage (to avoid amplicon dropouts and false negatives). And finally, for each variant, the metrics assessed were
coverage ≥500×, allelic frequency of ≥5%, and strand bias between 0.40 and 0.59.
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detected (Figure 2) with a median of 2 variants and a range of 0 to 7
variants per case (45 samples with 0 variant [wild type]; 145 samples
with 1 variant; 132 samples with 2 variants; 58 samples with 3
variants; 15 samples with 4 variants; 2 samples with 5 variants; and 1
sample [the LCNEC case] with 7 variants).
Mutations detected in BRAF, EGFR, ERBB2, KRAS, NRAS,
and PIK3CA were considered potentially actionable. For the purpose
of this manuscript, we defined actionable as any variant that either has
an FDA-approved therapy assigned to it or for which there is a clinical
trial indication. Such actionable mutations were identified in 237
samples, most commonly in KRAS (n= 151, 37.9%), EGFR (n= 44,
11.1%; excluding 6 secondary p. T790 M mutations), BRAF (n= 19,
4.8%) and PIK3CA (n= 17, 4.3%). Potentially actionable mutations
were detected in 60% of samples (237/398). The breakdown of the
specific mutations identified in the genes considered actionable is
shown in Figure 3 and Table S1. One hundred sixteen samples had
variants detected in other genes that are currently not clinicallyLung core biopsy
28%
Regional LN FNA
23%Excision of primary
15%
Metastatic sites (other 
than regional LN)
13%
Lung FNA
10%
Fluid (pleural/ 
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Consult, NOS
4%
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2%
Figure 1. Distribution of sample types that were successfully
sequenced (n=398). LN – lymph node; FNA – Fine needle aspiration.actionable, and 45 samples had no mutations detected with the 50
gene panel.
The vast majority of identified potentially actionable mutations were
single nucleotide variants (205) followed by insertions and deletions
(31) and only 1 frame shift mutation. Within EGFR, common and rare
mutations were detected in exons 18 to 21 including known activating
mutations p. G719C, exon 19 deletions, and p. L858R as well as
resistance mutations including p. L747S, p. L761I, exon 20 insertions,
p. T790M, and p. L861Q. The 6 samples that had p. T790M
mutations also had a coexisting exon 19 deletion, consistent with
acquired resistance. Interestingly, within the 1 sample that harbored
EGFR p. L747S, a described acquired resistance mutation, no other
mutations were identified; it is currently not known if this patient was
tyrosine kinase inhibitor (EGFR TKI) naive. Four ERBB2 exon 20
mutations and 2 NRAS codon 61 mutations were identified. And in
BRAF, 19 mutations were identified, 7 of which were p. V600E (37%)
with 10 (53%) occurring in exon 11.
We also identified co-occurrence of some of the most frequently
altered and clinically significant genes (Figure 4). Not surprisingly,
TP53 mutations co-occurred with mutations in KRAS, EGFR,
BRAF, PIK3CA, NRAS, and STK11. STK11 mutations were most
commonly seen in association with KRAS mutations. PIK3CA
mutations were only rarely identified co-occurring with other driver
mutations in KRAS or EGFR. Similar to prior reports in lung ADC,
all mutations in EGFR, KRAS, and BRAF were mutually exclusive in
our patient population. Interestingly, we also noticed a mutually
exclusive pattern among some additional genes: SMO, SMARCB1,
SMAD4, RET, RB1, PTPN11, PTEN, PIK3CA, and PDGFRA
(which is currently of uncertain significance).
Patients with Multiple Tumors Tested
Although most of the patients who had testing performed on
multiple samples were due to an insufficient quantity of material on
the first sample, we did have a cohort of patients who had multiple
tumors tested. Four patients had multiple synchronous lung tumors
tested: three bilateral and one ipsilateral. In all four cases, divergent
mutational profiles were identified (Table 2). Eight patients either
had the primary lung tumor and metastatic sites (four patients) or
multiple metastatic sites tested. Metastatic sites included LN
metastases, pleural fluid or biopsy, adrenal and liver metastases,
brain metastases, and a skin metastasis. Among these tumors, there
were a consistent mutational profile among primary tumors and
metastatic sites and identification of EGFR p. T790M resistance
mutations in the metastatic tumors of two patients (Table 2).
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Figure 2. Number of cases with variants detected in the respective 50 genes included in the NGS assay.
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Next-generation sequencing is a powerful tool that allows for testing
multiple targets in multiple genes in multiple patients simultaneously.
NGS assays are rapidly being adopted in clinical laboratories for this
purpose, replacing individual single gene assays and expanding the
testing capacity that can be performed on relatively small amounts of
tissue. Here, we report from our experience using the AmpliSeq 50
gene Cancer Hotspot Panel v2 in the clinical testing of a large number
of lung adenocarcinomas. The Ion Torrent platform requires very
little input DNA (10 ng), thus allowing for successful testing of small
biopsy and FNA specimens. As we showed, we had a very high success
rate with theses samples. Surprisingly, our highest failure rate was
with lung core needle biopsies. We speculate that this may in part be
due to challenges of getting the fixed tumor cells into solution when
associated with a fibrous background/scar as opposed to FNA cell
blocks where the cells are already in solution prior to fixation.0 20 40 60
No potentially actionable mutations
KRAS Codon 12
EGFR Exon 19
PIK3CA
EGFR Exon 21
KRAS Codon 13
KRAS Codon 61
BRAF non-V600
BRAF V600
EGFR Exon 20 T790M
ERBB2 Exon 20 ins
EGFR Exon 20 ins
NRAS Codon 61
EGFR Exon 18
Figure 3. Clinically actionaAdditionally, many of the lung core biopsy procedures at our
institution have immediate onsite cytologic assessment performed via
touch imprint preparations. Transfer of tumor cells to the cytology
slides may result in some decreased tumor cellularity in the
formalin-fixed paraffin tissue block. Requesting additional passes,
minimizing tissue “rolling,” and preparing unstained slides upfront
are measures that we have utilized to increase molecular testing yield.
In our population, we identified a higher percentage of KRAS
mutations (37.9% vs 28% and 26%) and fewer EGFR mutations
(11.1% vs 14% and 20%) than reported by Hageman et al. and Dogan
et al., respectively [9,10]. This may be due to different prevalence of
smoking and ethnicity in the different sample sets or selection bias of the
various populations or testing methods (for instance, we tested multiple
samples from the same patient in several instances).
Using this targeted NGS panel, we identified clinically actionable
rare mutations that have specific therapeutic significance that would80 100 120 140 160 180
ble mutations identified.
Potentially 
actionable 
(237)
Uncertain 
significance 
(116)
Wild type 
(45)
KRAS
151
EGFR
44
BRAF
19
PIK3CA
17
ERBB2
4
NRAS
2
A B 
T790M
5
KRAS
84
TP53
82
47PIK3CA
4 9
3
STK11
12
17
8
NRAS
2
EGFR
24
19
1
1
BRAF
12
1
6
Figure 4. Co-occurrence of clinically actionable mutations.
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laboratory. Examples include detection of EGFR and ERBB2 exon 20
insertions, EGFR p. T790M secondary resistance mutations, as well
as additional variants within EGFR, KRAS, and BRAF (Table S1 and
Figure 3) [11]. Recently, the efficacy of afatinib, a second-generation
irreversible TKI, was reviewed in 75 patients with uncommon EGFR
mutations that had been enrolled in the LUX-lung trials 2, 3, and 6.
Whereas afatinib was active in patients with uncommon mutations
including p. L861Q (which is typically resistant to first-generation
TKIs) and p. G719X, the response rate was low in tumors with exon
20 insertions [12]. EGFR exon 20 insertions are biologically different
than common EGFR mutations because they do not affect the
ATP-binding pocket of the kinase domain but rather the c-helix
domain. This results in increased kinase activity but decreased affinity
to TKIs [12,13]. Alternative therapies for these patients are needed.
Currently, a phase 2 clinical trial of a heat shock protein 90 inhibitor
(AUY922) is under way in patients with EGFR exon 20 insertion
mutations (NCT01854034). Another EGFR mutation we detected,Table 2. In a Select Number of Patients, Multiple Tumors Were Tested: Mutations Identified in Fo
Synchronous Tumors Site Mutations Identified Site
Patient S1 Lung, left EGFR L858R Lung, right
Patient S2 Lung, left KRAS G12 V; ATM G2869R Lung, right
Patient S3 Lung, left KRAS G12 V; CDKN2A c.151-2 A N T Lung, right
Patient S4 Lung, right KRAS G12C; TP53 R158L Lung, right
Metastatic tumors
Patient M1 LN EGFR ex19 del Pleural fluid
Patient M2 Lung, right EGFR ex 19 del Pleural fluid
Patient M3 Pleural fluid EGFR ex 19 del; TP53 H193Y Adrenal metastas
Patient M4 Lung None detected Subcutaneous m
Patient M5 Lung ERBB2 ex 20 ins; TP53 Y88C Brain metastasis
Patient M6 Lung FGFR1 A268P; TP53 A159P LN
Patient M7 Pleural biopsy TP53 P190L LN
Patient M8 LN KRAS G12C; IDH1 R132L Brain metastasis
S, synchronous tumors; M, metastatic tumors; LN, lymph node.an exon 7 p. A289V, was classified as a variant of uncertain
significance; this mutation in the EGFR extracellular domain is
commonly seen in glioblastomas, but the significance is uncertain in
NSCLC [14].
ERBB2 exon 20 insertion mutations are identified in a small
proportion of ADCs (approximately 2%) and also define a distinct
subset of tumors. The most common mutation is a 12-bp insertion
(p. A775 G776insYVMA) found in 50% to 80% of ERBB2 mutant
lung cancers [15,16]. ERBB2 exon 20 mutations are mutually
exclusive with common EGFR and KRAS mutations and are distinct
from tumors showing ERBB2 amplification [17]. ERBB2 targeted
therapies for this indication are available including lapatinib,
dacomitinib, and afatinib (NCT02369484) [17].
In BRAF, we identified 19 mutations; however, only 7 of these
(37%) were p. V600E and 10 (53%) occurred in exon 11. These
findings are consistent with those in a recent report by Carter et al.
that demonstrated a broad spectrum of unique BRAF mutations in
lung cancers with a high prevalence of mutations located in exon 11ur Cases with Synchronous Tumors and Eight Cases with Metastatic Tumors
Mutations Identified Site Mutations Identified
TP53 H61R
KRAS G12C; CCNTB1 S37C
STK11 D194Y
PIK3CA R335S; TP53 G245C
EGFR ex 19 del; EGFR T790 M Pleural fluid EGFR ex 19 del; EGFR T790 M
EGFR ex 19 del
is EGFR ex 19 del; TP53 H193Y Liver metastasis EGFR ex 19 del; EGFR T790 M;
TP53 H193Y
etastasis None detected
ERBB2 ex 20 ins; TP53 Y88C
FGFR1 A268P; TP53 A159P
TP53 P190L; PTEN Y16*
KRAS G12C; IDH1 R132L
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with non–codon 600 mutations is unclear, although some report that
tumors with exon 11 or mutations impairing the kinase activity are
predicted to be unresponsive to current BRAF inhibitors [18,19].
However, preclinical studies suggest that dasatinib and MEK
inhibitors with or without a BRAF inhibitor may have efficacy in
such patients [18,20]. Presently, patients with non-V600 mutations
are also eligible for an NCI-Match trial with the MEK inhibitor
trametinib (NCT02465060). We also detected mutations in KIT,
IDH1, IDH2, PTEN, CDKN2A, and JAK2 that are well characterized
in other tumor types and may allow patients to meet eligibility criteria
for novel clinical trials. Patients with mutations that not known to be
actionable are referred to the Norris Cotton Cancer Center Molecular
Tumor Board [21].
The detection of multiple, co-occurring, potentially actionable
mutations in an individual tumor represents an advance in molecular
pathology with possible significant clinical, therapeutic, and research
implications based on the different combinations of mutations. Eng
et al. recently published their data on the impact of concurrent
PIK3CA mutations with other oncogenic driver mutations on
response to therapy. Overall, they found that a concurrent PIK3CA
mutation was a poor prognostic factor in EGFR or KRAS mutant
lung ADC, although it did not significantly alter the benefit of EGFR
TKI therapy in the EGFR mutant patients [22]. However,
co-occurrence with KRAS, as was identified in three cases in our
study, may in fact be a contraindication for targeted therapies as
mutations in both of these genes effect the PI3K-AKT pathway and
alternative therapies such as immunotherapies may be more effective.
Overall, among EGFR and KRAS mutant lung cancers, those with a
concurrent PIK3CA mutation are unique with prognostic and
predictive implications.
STK11 mutations, commonly identified in lung ADC, often
coexist with KRAS mutations and likely also have a confounding
prognostic significance. Pécuchet et al., who examined a cohort of
567 resected nonsquamous NSCLC patients and validated their
findings in 2 publically available datasets, found that patients with
STK11 mutations, specifically in exons 1 and 2, had a significantly
worse prognosis than wild-type tumors or tumors with exon 3 to 9
mutations [23]. Recent reports also suggest that co-occurring
genomic alterations can define heterogeneous subsets of KRAS-mu-
tant lung ADC with distinct clinical implications [24]. Skoulidis et al.
describe three robust subsets of KRAS-mutant ADC dominated by
co-occurring mutations in STK11, TP53, and CDKN2A/B inactiva-
tion. They identified differences in drug sensitivity patterns including
expression of PD-L1 and susceptibility to HSP90-inhibitor therapy,
significant findings given the challenges to date of therapeutically
targeting KRAS-mutant lung ADC [24].
In our study, we have shown the utility of the Ion Torrent Ampliseq
technology for clinical genotyping of NSCLC which requires very little
input DNA and can successfully be performed on small biopsy and
cytology specimens. This targetedNGS approach allows for detection of
common and also rare clinically actionable mutations and profiles of
co-mutations in multiple patients simultaneously.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.neo.2016.07.010.
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